This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Threshold's Pancreatic Cancer Drug Boosts Survival -- With an Asterisk

Stocks in this article: THLD CELG CLVS PPHM

Updated with new information.

SOUTH SAN FRANCISCO ( TheStreet) -- Threshold Pharmaceuticals' (THLD) TH-302 boosted the survival of pancreatic patients, but data from the mid-stage study raised concerns and caused the stock to fall.

At the median, TH-302 survival data are impressive. The combination of a higher dose of TH-302 plus gemcitabine yielded a median overall survival of 9.2 months versus 6.9 months for gemcitabine alone. That's a median survival benefit of 2.3 months, which is meaningful for any pancreatic cancer trial. Consider that Roche and Astellas' Tarceva was approved in pancreatic cancer based on a two-week survival benefit.

The broader survival analysis of the same Threshold study does not look as favorable, however. Adding TH-302 to gemcitabine only reduced the relative risk of death by 4.5% over gemcitabine alone -- a small benefit that was far from statistical significance.

Threshold shares fell $1.67 or 19% to $7.05 in Monday trading, sparking conversation on Twitter over how best to evaluate TH-302 and its potential in pancreatic cancer.

Based on these phase II data, Threshold and partner Merck KGaA are in the process of designing a phase III study of TH-302 in pancreatic cancer.

Threshold announced the survival data from the TH-302 phase II pancreatic cancer study Monday in advance of presentation at the European Society of Medical Oncology meeting on Sept. 29.

This phase II study enrolled 214 pancreatic cancer patients and randomized them to treatment with TH-302/gemcitabine or gemcitabine alone. As presented earlier this year, treatment with TH-302/gemcitabine led to a two-month improvement in progression-free survival of 5.6 months compared to 3.6 months for gemcitabine alone. The benefit in PFS was statistically significant, although there were some imbalances in patients' baseline criteria that favored TH-302 and may have skewed results.

Approximately one-third of patients in the gemcitabine arm "crossed over" to receive TH-302 after tumor progression. Threshold says this crossover did contribute to an increase in survival in the study's control arm. In older studies, including the pivotal study of Tarceva, patients treated with gemcitabine lived about six months.

Celgene (CELG), Clovis Oncology (CLVS) and Peregrine Pharmaceuticals (PPHM) are expected to announce results from their own closely watched pancreatic cancer drug trials before the end of the year.

Prior to Monday's fall, Threshold shares were up more than 500% this year based on optimism for TH-302.

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to

>To submit a news tip, send an email to:

Follow TheStreet on Twitter and become a fan on Facebook.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs